Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ORAL Shift: Tofacitinib MTX Withdrawal in RA
NCT02831855Phase 4Completed
- Sponsor
- Pfizer
- Start
- Sep 2016
- Primary completion
- Nov 2018
- Modality
- Small Molecules
- Countries
- 16
01
Overview
A Phase 4 trial of tofacitinib oral solution in rheumatoid arthritis (RA), sponsored by Pfizer. Started Sep 2016; status: completed.
02
Drugs
tofacitinib oral solution
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on NCT02831855.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02831855.